EUVIMEDEUVIMED entdecken
Crossref

Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action

Ebtsam S Abdel-Lah iD, Nashwa Hamad iD, Amira F Taha, Wafaa H Mohamed, Mariam A Fawy, Abdelraheim H Attaai iD, Fatma Y A Abbas, Hoda S Sherkawy, Ahmed Abdelwarith, Marwa G Gamea

Drug Development Research · 2025

DOI: 10.1002/ddr.70180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Ebtsam S Abdel-Lah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt. Hauptthemen laut MEDLINE: Rivastigmine, Glucosides, Neuroprotective Agents, Alzheimer Disease. Die Arbeit nennt 89 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the neuroprotective potential of empagliflozin (EMPA) as antidiabetic drug on glucose metabolism, comparing it to rivastigmine (RIVA) as standard treatment for Alzheimer's disease (AD), and their combination. Male rats were sorted into five groups. Group I served as the control, while groups II, III, IV, and V received the scopolamine plus heavy metal mixture for AD induction. Groups III and IV were administered RIVA and EMPA, respectively, and group V received both treatments. Cognitive function was evaluated behaviorally. Subsequently, glucose levels, acetylcholinesterase, oxidative stress, and inflammatory markers were assessed. Alongside the brain histopathological changes, the expression of phosphorylated tau protein was assessed. Moreover, glycolytic enzymes and glucose transporters were assessed using PCR analysis. The findings were attributed to a notable suppressive impact of EMPA on lipid peroxidation, acetylcholinesterase, glucose levels, phosphorylated tau protein, pro‐inflammatory cytokines, and neuropathological changes, while enhancing antioxidant and interleukin‐10 levels. It also improves glucose metabolism. The findings suggest that EMPA may be a viable candidate for future therapeutic exploration in AD, which has a multifaceted mechanism of action encompassing anti‐neuroinflammation, antioxidant stress, and enhanced glucose metabolism, as well as decreased acetylcholinesterase activity and phosphorylated tau protein levels. Interestingly, combined treatment showed a superior effect than EMPA alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivastigmineGlucosidesNeuroprotective AgentsAlzheimer DiseaseBenzhydryl CompoundsAnimalsMaleRatsDisease Models, AnimalOxidative StressAcetylcholinesteraseGlucoseBrainRats, WistarSodium-Glucose Transporter 2 Inhibitorstau ProteinsDrug Therapy, CombinationLipid Peroxidation

Stichwörter der Autor:innen

Alzheimer's diseaseempagliflozinglucose transportersheavy metal mixturesratsrivastigminescopolamine

Substanzen

RivastigmineGlucosidesNeuroprotective AgentsBenzhydryl CompoundsempagliflozinAcetylcholinesteraseGlucoseSodium-Glucose Transporter 2 Inhibitorstau Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt.
  • Department of Pharmacology, School of Veterinary Medicine, Badr University in Assiut, Naser city, Egypt.
  • Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
  • Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt.
  • Department of Zoology, Faculty of Science, South Valley University, Qena, Egypt.

ORCID-Profile: Ebtsam S Abdel-Lah, Nashwa Hamad, Abdelraheim H Attaai

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Abdel-Lah, E. S., Hamad, N., Taha, A. F., Mohamed, W. H., Fawy, M. A., Attaai, A. H., Abbas, F. Y. A., Sherkawy, H. S., Abdelwarith, A., & Gamea, M. G. (2025). Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action. Drug Development Research. https://doi.org/10.1002/ddr.70180

Vancouver

Abdel-Lah ES, Hamad N, Taha AF, Mohamed WH, Fawy MA, Attaai AH, et al. Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action. Drug Development Research. 2025. doi:10.1002/ddr.70180

BibTeX
@article{AbdelLah2025,
  author = {Abdel-Lah, Ebtsam S and Hamad, Nashwa and Taha, Amira F and Mohamed, Wafaa H and Fawy, Mariam A and Attaai, Abdelraheim H and Abbas, Fatma Y A and Sherkawy, Hoda S and Abdelwarith, Ahmed and Gamea, Marwa G},
  title = {Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70180}
}
Kostenlos starten →